AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd's Syndicate 1902, for its Phase III clinical trial ...
AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the shelf-life of its veterinary medicine MASIVET® from 36 months to ...
PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM, SUSPENDING SOME NON-PRIORITY CLINICAL TRIALS TO FOCUS ON TWO CLINICAL ...
(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announced today the results from a phase 3 ...
i) Approval by several European countries to initiate the confirmatory Phase 3 trial AB Science announced in July 2025 that the confirmatory Phase 3 trial with masitinib in amyotrophic lateral ...
Ab Science ((ABSCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
AB Science SA (Euronext - FR0010557264 - AB) announces that its stock continues to be covered by Stonegate Capital Partners, a leading independent US-based research and investor outreach firm, which ...
AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease (i.e ...
AB Science SA (Euronext - FR0010557264 - AB) today announces that The Life Sciences Magazine, a leading publication in the fields of healthcare and medical advancements, has featured an exclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results